Miacom Diagnostics respiFISH Masterpanel Is Reimbursed By Health Insurance Funds In Croatia

• IVD tools for direct testing of respiratory samples are being used at Children’s Hospital Srebrnjak
• More effective therapies and therefore reduced costs

DUESSELDORF, Germany--(BUSINESS WIRE)--miacom diagnostics, founded in Duesseldorf, Germany in 2006, specializes in the development and commercialization of diagnostics tools for identification and differentiation of bacteria in acute infectious diseases. After the continuing success of miacom’s hemoFISH^® unique multiplex Identification system for positive blood cultures, miacom offers a new line of kits to identify bacteria in pneumonia patients directly from respiratory fluids. With the respiFISH^® Masterpanel, clinicians will be able to simultaneously identify the most clinically relevant Gram negative and Gram positive bacteria within 30 min directly from sputum, bronchial or tracheal secretions. This means an essential step forward in miacom´s vision to develop faster and better diagnostic methods than the ones currently available on the market.

“We are, of course, very proud that our recently approved respiFISH Masterpanel now is being used as a routine procedure in daily clinical practice. Also hospitals and diagnostic centres in Germany are looking at using similar strategies for reimbursement of costs.”

Miacom announces that “Children´s Hospital Srebrnjak” in Croatia now uses the recently CE market respiFISH^® Masterpanel as a routine tool for diagnosis in clinical practice. Children’s Hospital Srebrnjak is a central care institution for children and adolescents in Croatia and cares for more than 11,500 patients annually and regularly performs more than a million medical procedures each year. As children are at a higher risk of catching pneumonia, in clinical practice a timely targeted intervention is critical for the treatment of pneumonia patients and prevention of it escalating to sepsis. Many other hospitals in Europe are now evaluating the respiFISH Panel for routine use.

respiFISH Masterpanel covers 14 of the most common bacteria causing healthcare-associated pneumonia and thus provides physicians an indispensable tool for targeted antibiotic therapy in those patients. The test is designed to support routine diagnostics and results can be reported back to the ICU consultant in time together with the results of a Gram stain. Rapid diagnosis can save lives by enabling more effective treatment of the pneumonia infection and by lowering the risk of sepsis. In addition it reduces costs and overall healthcare spending by minimizing the use of broad antibiotics and potential shortening hospital stay.

“We are, of course, very proud that our recently approved respiFISH Masterpanel now is being used as a routine procedure in daily clinical practice. Also hospitals and diagnostic centres in Germany are looking at using similar strategies for reimbursement of costs. ” said Dr. Mirko Stange, CEO of miacom diagnostics GmbH.

About miacom diagnostics (www.miacom-diagnostics.de)

Miacom diagnostics specializes in in-vitro diagnostic tests for pathogens causing acute systemic diseases. All kits enable a simultaneous detection of clinically relevant pathogens directly from specimens, and deliver results within 30 minutes. In Europe, Miacom has already commercialized several rapid tests, including diagnostic tools for important systemic infectious diseases such as sepsis and pneumonia. All kits are designed as affordable multiplex tests that detect and differentiate up to 14 bacterial targets on a single microscope slide.